496 related articles for article (PubMed ID: 27569653)
1. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
[TBL] [Abstract][Full Text] [Related]
4. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
[TBL] [Abstract][Full Text] [Related]
5. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
Liska D; Chen CT; Bachleitner-Hofmann T; Christensen JG; Weiser MR
Clin Cancer Res; 2011 Feb; 17(3):472-82. PubMed ID: 21098338
[TBL] [Abstract][Full Text] [Related]
6. Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M; Xiao Q; Hu J; Cheng F; Zhang P; Zong W; Tang Q; Li X; Mao F; He Y; Yu X; Wan F; Lei T; Guo D; Wang B
Cancer Gene Ther; 2020 Dec; 27(12):878-897. PubMed ID: 31988476
[TBL] [Abstract][Full Text] [Related]
7. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
[TBL] [Abstract][Full Text] [Related]
8. AXL mediates resistance to cetuximab therapy.
Brand TM; Iida M; Stein AP; Corrigan KL; Braverman CM; Luthar N; Toulany M; Gill PS; Salgia R; Kimple RJ; Wheeler DL
Cancer Res; 2014 Sep; 74(18):5152-64. PubMed ID: 25136066
[TBL] [Abstract][Full Text] [Related]
9. Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer.
Zulkifli A; Tan FH; Areeb Z; Stuart SF; Gomez J; Paradiso L; Luwor RB
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281166
[TBL] [Abstract][Full Text] [Related]
10. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.
Ou WB; Hubert C; Corson JM; Bueno R; Flynn DL; Sugarbaker DJ; Fletcher JA
Neoplasia; 2011 Jan; 13(1):12-22. PubMed ID: 21245936
[TBL] [Abstract][Full Text] [Related]
11. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.
Quesnelle KM; Grandis JR
Clin Cancer Res; 2011 Sep; 17(18):5935-44. PubMed ID: 21791633
[TBL] [Abstract][Full Text] [Related]
12. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
Solanes-Casado S; Cebrián A; Rodríguez-Remírez M; Mahíllo I; García-García L; Río-Vilariño A; Baños N; de Cárcer G; Monfort-Vengut A; Castellano V; Fernández-Aceñero MJ; García-Foncillas J; Del Puerto-Nevado L
Biomed Pharmacother; 2021 Dec; 144():112347. PubMed ID: 34700228
[TBL] [Abstract][Full Text] [Related]
13. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.
Iida M; Bahrar H; Brand TM; Pearson HE; Coan JP; Orbuch RA; Flanigan BG; Swick AD; Prabakaran PJ; Lantto J; Horak ID; Kragh M; Salgia R; Kimple RJ; Wheeler DL
Mol Cancer Ther; 2016 Sep; 15(9):2175-86. PubMed ID: 27422810
[TBL] [Abstract][Full Text] [Related]
14. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
[TBL] [Abstract][Full Text] [Related]
15. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.
Jiao Y; Ou W; Meng F; Zhou H; Wang A
Mol Cancer; 2011 Sep; 10():125. PubMed ID: 21962244
[TBL] [Abstract][Full Text] [Related]
16. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
17. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
[TBL] [Abstract][Full Text] [Related]
18. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S
Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704
[TBL] [Abstract][Full Text] [Related]
19. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
[TBL] [Abstract][Full Text] [Related]
20. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
